Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny vesicles could hold the key to better islet transplants

NCT ID NCT07812974

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether extracellular vesicles released by pancreatic islets can indicate islet quality and be used to improve their fitness before transplantation. The trial involves adults with type 1 diabetes who are on the waiting list for an islet transplant. The goal is to develop a way to precondition islets with protective vesicles, which may help more of the transplanted islets survive and function, reducing the need for multiple donor infusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracellular vesicle-based islet preconditioning
What this could lead to
If the approach works, it could help doctors select the healthiest islets for transplant and treat them before infusion, potentially improving insulin independence rates and reducing the need for multiple donor infusions.
What could go wrong
This is an early-stage study with a small number of participants, so the findings may not apply broadly. The link between extracellular vesicles and islet quality is still being explored, and the preconditioning strategy may not translate into better transplant outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with type 1 diabetes

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with no upper age limit * Men or women * Patients with type 1 diabetes * Patients on the waiting list for a pancreatic islet transplant (Agence de Biomédecine) * Patients who have given their consent for their data to be reused for the purposes of this research Exclusion Criteria: * Pregnant women * Patients under guardianship or administration * Individuals subject to judicial protection measures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes (T1D) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes (T1D)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux universitaires de Strasbourg

    Strasbourg, 67200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.